Ibrutinib (Imbruvica) as monotherapy for people who have had treatment for CLL and are unable to have further chemotherapy
In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assessed the advantages and disadvantages of ibrutinib (trade name: Imbruvica) for people who have had treatment for chronic lymphocytic leukemia (CLL) and are unable to have chemotherapy. The manufacturer provided one study involving about 391 people. 196 people had the standard treatment with ofatumumab, while 195 people received ibrutinib. In addition, all participants received best supportive care (BSC).
What are the advantages of ibrutinib?
- Life expectancy: There was weak evidence that ibrutinib can increase life expectancy. But it is unclear how great this advantage is.
What remains unanswered?
Because the study on ibrutinib was only of limited use, several issues remain unanswered. In particular, it is not possible to rule out that severe side effects are more common with ibrutinib. Quality of life could also become noticeably worse with ibrutinib.
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ibrutinib – Benefit assessment according to §35a Social Code Book V; Dossier assessment; Commission A16-04. April 28, 2016. (IQWiG reports; Volume 386).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Ibrutinib (chronic lymphocytic leukemia, mantle cell lymphoma) – Addendum to Commission A16-04; Commission A16-34. June 24, 2016. (IQWiG reports; Volume 403).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.